Posted by Michael Wonder on 03 May 2021
TLV reconsiders subsidy for eleven TNF alfa inhibitors included in the high-cost protection
30 April 2021 - Today, eleven subcutaneous TNF-alpha inhibitors are included in the high-cost protection.
For eight of the medicines, there are side agreements between the regions and the companies that market the respective medicines.
The side agreements mean that the cost of using these medicines is reduced, as part of the cost is reimbursed by the pharmaceutical companies to the regions, so-called reimbursement.
